New review charts a roadmap for biologically informed psychiatric diagnosis using biomarkers and AI.
Key Details
- 1Psychiatric diagnosis still relies on symptom checklists, lacking biological grounding.
- 2Emerging frameworks combine molecular/neuroimaging biomarkers, digital phenotyping, and machine learning integration.
- 3Large consortia (e.g., ENIGMA) tie neuroimaging findings to psychiatric conditions like schizophrenia and depression.
- 4Molecular diagnostic tests (e.g., VeriPsych, EDIT-B) have reached limited clinical adoption; most candidate biomarkers lack clinical utility so far.
- 5AI and multimodal models show promise but face challenges with limited psychiatric datasets, lack of explainability, and real-world validation.
- 6Review emphasizes that objective biological measurement should complement—not replace—clinical judgment.
Why It Matters
For radiology and imaging AI professionals, this review highlights the expanding role of neuroimaging, molecular markers, and AI in mental health, a field historically reliant on subjective measures. Robust integration of imaging and digital phenotyping could reshape diagnosis, steering research and technology development towards actionable and explainable clinical tools.
Source
EurekAlert
Related News
•EurekAlert
MSKAI Unveils AI Tool for Embryo Cell Analysis and Imaging-Driven Cancer Insights
MSK researchers employ AI and advanced imaging to reveal cancer mechanisms and track embryonic development at the single-cell level.
•EurekAlert
AI-Driven Home Sensors Enable Privacy-Preserving Health Emergency Detection
Researchers have developed an AI-powered home monitoring system using radar and thermal sensors to detect health emergencies and support elderly independent living.
•EurekAlert
New Study Urges 'Green AI' Practices in Medical Imaging and Healthcare
A new review highlights the urgent need for sustainable AI practices in healthcare, with emphasis on environmental impacts from applications like medical imaging.